It produces an amazing 20% weight loss on average and is the first drug that targets both GLP-1 and GIP, resulting in more effective glycemic control and appetite suppression. Reductions in body weight have also been shown to be greater with tirzepatide versus semaglutide and increased with the dose: 1.9 kg for 5 mg, 3.6 kg for 10 mg, and 5.5 kg for 15mg.
Suppresses appetite and prolongs feelings of fullness allowing for caloric reduction.
Delays gastric emptying which causes food to stay in the stomach longer, producing a feeling of fullness and satiety.
Modulates neural signals mediated by GIP and GLP-1 receptors that regulate gastrointestinal motility and feeding behaviors. This optimizes satiation.
May increase resting energy expenditure through thermogenic effects, promoting greater calorie burning.
When combined with diet and exercise counseling, GLP-1 medication enables patients to follow lower calorie meal plans and increase physical activity more comfortably and effectively.